메뉴 건너뛰기




Volumn 32, Issue 15, 2011, Pages 1832-1834

Erratum: Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: More support for cardiovascular outcome assessments (European Heart Journal (2011) 32 (1832-1834) DOI: 10.1093/eurheartj/ehr019);Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: More support for cardiovascular outcome assessments

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; MEGLITINIDE; METFORMIN; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

EID: 80051499525     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs094     Document Type: Erratum
Times cited : (23)

References (16)
  • 1
    • 38349192580 scopus 로고    scopus 로고
    • New drugs for the treatment of diabetes mellitus: Part I: Thiazolidinediones and their evolving cardiovascular implications
    • McGuire DK, Inzucchi SE. New drugs for the treatment of diabetes mellitus: part I: thiazolidinediones and their evolving cardiovascular implications. Circulation 2008;117:440-449.
    • (2008) Circulation , vol.117 , pp. 440-449
    • McGuire, D.K.1    Inzucchi, S.E.2
  • 2
    • 41049110803 scopus 로고    scopus 로고
    • New drugs for the treatment of diabetes: Part II: Incretin-based therapy and beyond
    • Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation 2008;117:574-584.
    • (2008) Circulation , vol.117 , pp. 574-584
    • Inzucchi, S.E.1    McGuire, D.K.2
  • 3
    • 67650233277 scopus 로고    scopus 로고
    • Cardiovascular disease and type 2 diabetes mellitus: Regulating glucose and regulating drugs
    • Gore MO, McGuire DK. Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs. Curr Cardiol Rep 2009;11:258-263.
    • (2009) Curr Cardiol Rep , vol.11 , pp. 258-263
    • Gore, M.O.1    McGuire, D.K.2
  • 4
    • 79958197888 scopus 로고    scopus 로고
    • Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study
    • First published on 6 April 2011. doi: 10.1093/eurheartj/ehr077
    • Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, Køber L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32:1900-1908. First published on 6 April 2011. doi: 10.1093/eurheartj/ ehr077.
    • (2011) Eur Heart J , vol.32 , pp. 1900-1908
    • Schramm, T.K.1    Gislason, G.H.2    Vaag, A.3    Rasmussen, J.N.4    Folke, F.5    Hansen, M.L.6    Fosbøl, E.L.7    Køber, L.8    Norgaard, M.L.9    Madsen, M.10    Hansen, P.R.11    Torp-Pedersen, C.12
  • 5
    • 0032511566 scopus 로고    scopus 로고
    • Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
    • (1998) Lancet , vol.352 , pp. 854-865
  • 6
    • 0015153101 scopus 로고
    • Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results
    • Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 1971;218:1400-1410.
    • (1971) JAMA , vol.218 , pp. 1400-1410
    • Goldner, M.G.1    Knatterud, G.L.2    Prout, T.E.3
  • 7
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
    • UK Prospective Diabetes Study (UKPDS) Group
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-853.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 9
    • 60449089649 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
    • (2009) Diabetes Care , vol.32 , pp. 193-203
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3    Ferrannini, E.4    Holman, R.R.5    Sherwin, R.6    Zinman, B.7
  • 10
    • 0036894342 scopus 로고    scopus 로고
    • Sulfonylurea stimulation of insulin secretion
    • Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002;51 Suppl 3:S368-S376. (Pubitemid 35403418)
    • (2002) Diabetes , vol.51 , Issue.SUPPL. 3
    • Proks, P.1    Reimann, F.2    Green, N.3    Gribble, F.4    Ashcroft, F.5
  • 11
    • 9444284451 scopus 로고    scopus 로고
    • + channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium
    • DOI 10.2337/diabetes.53.suppl-3.S156
    • Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004;53 Suppl 3:S156-S164. (Pubitemid 39564538)
    • (2004) Diabetes , vol.53 , Issue.SUPPL. 3
    • Quast, U.1    Stephan, D.2    Bieger, S.3    Russ, U.4
  • 12
    • 27844440474 scopus 로고    scopus 로고
    • Realizing the clinical potential of ischemic preconditioning and postconditioning
    • DOI 10.1038/ncpcardio0346, PII N0346
    • Yellon DM, Hausenloy DJ. Realizing the clinical potential of ischemic preconditioning and postconditioning. Nat Clin Pract Cardiovasc Med 2005;2:568-575. (Pubitemid 41655660)
    • (2005) Nature Clinical Practice Cardiovascular Medicine , vol.2 , Issue.11 , pp. 568-575
    • Yellon, D.M.1    Hausenloy, D.J.2
  • 14
    • 0031451561 scopus 로고    scopus 로고
    • Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease [1]
    • DOI 10.1007/s001250050855
    • Muhlhauser I, Sawicki PT, Berger M. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease. Diabetologia 1997;40:1492-1493. (Pubitemid 28004946)
    • (1997) Diabetologia , vol.40 , Issue.12 , pp. 1492-1493
    • Muhlhauser, I.1    Sawicki, P.T.2    Berger, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.